Search

Displaying results 2141 - 2150 of 10000 in total
  1. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    Onasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. … [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.

  2. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is a peripheral vasodilator. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.

  3. Drug

    Isopropyl myristate

    go.drugbank.com/drugs/DB13966
    Approved

    Isopropyl myristate is a moisturizer with polar characteristics used in cosmetics and topical medical preparations to ameliorate the skin absorption. … [A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966].

  4. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist … Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).

  5. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.

    Categories: Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor
  6. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations

  7. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo. … Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology

  8. Drug

    Pergolide

    go.drugbank.com/drugs/DB01186
    ApprovedVet approvedWithdrawn

    While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes. … The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007.

  9. Drug

    SIG-001

    go.drugbank.com/drugs/DB17826
    Investigational

    SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer

  10. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. … The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients